Atrial flutter with 1 : 1 atrioventricular conduction after administration of vernakalant for atrial fibrillation.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Atrial flutter with 1 : 1 atrioventricular conduction after administration of vernakalant for atrial fibrillation Christine Franzini1*, Stephan Andreas Müller-Burri1, and Dipen C. Shah2 Department of Cardiology, Stadtspital Triemli, Birmensdorferstrasse 497, 8063 Zürich, Switzerland; and Department of Cardiology, Hôpitaux Universitaires de Genéve, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland * Corresponding author. Tel: +41 44 466 13 49; fax: +41 44 466 27 97, Email: [email protected] A44-year-oldhealthywomanpresentedwithatrialfibrillation.Vernakalantwasadministered.Organizationto2 : 1with transitionto1 : 1atrial flutter occurred. Vernakalant is a novel, effective, and relatively safe antiarrhythmic drug used for cardioversion of recent onset atrial fibrillation. Our case demonstrates, that in addition to the well-known adverse events, rapid 1 : 1 atrial flutter should be considered when using vernakalant.